Updated:
Regenstrief Institute
The Regenstrief Institute was founded in 1967 in Indianapolis through an endowment from manufacturing and appliance-discounting entrepreneur Sam Regenstrief.
Regenstrief Institute
The Regenstrief Institute was founded in 1967 in Indianapolis through an endowment from manufacturing and appliance-discounting entrepreneur Sam Regenstrief. The institute operates as a supporting organization to the Indiana University School of Medicine, a governance structure that embeds informatics researchers directly alongside clinicians at partner health systems including Eskenazi Health and IU Health. Sam Regenstrief's wealth originated from his eponymous discount appliance and electronics retail brand, which he sold in the mid-1960s, and a separate manufacturing operation. The institute's work spans biomedical informatics, health services research, and aging research. Its flagship creation is the Logical Observation Identifiers Names and Codes (LOINC) system, a universal standard for identifying medical laboratory observations that has been adopted in 175 countries. Operational partnerships extend to major pharmaceutical firms; Merck has collaborated with the institute on digital-health validation studies, and Eli Lilly has engaged on healthcare data initiatives. The deployment model is not venture capital but rather grant-funded research and technology development, often transitioning to non-profit licensing and open-source distribution. Regenstrief maintains a lean leadership structure. D. Craig Brater serves as board chair of the institute while concurrently leading the Regenstrief Foundation as president and CEO. In 2023, Rachel Patzer, an epidemiologist and transplant outcomes researcher, assumed the role of institute president and CEO, signaling a continued focus on data-driven health-equity research. The institute operates from its headquarters on Wishard Boulevard in Indianapolis and remains a component unit of Indiana University, with all faculty holding joint academic appointments. The institute's structural differentiator lies in its operational taxonomy: it is neither a pure grantmaking foundation nor a commercial health-tech incubator. It functions as a research operating entity whose intellectual property — most notably LOINC — is widely adopted by governments, hospital networks, and device manufacturers without recurring licensing fees. This open-infrastructure posture distinguishes it from university tech-transfer offices and for-profit clinical-software vendors.
General information
Firm type
Endowment / Foundation
Year founded
1967
Location
Region
North America
Country
United States
City
Indianapolis
Corporate office
1101 West 10th Street, Indianapolis, IN 46202, United States
Principals
D. Craig Brater
Board Chair, Regenstrief Institute; President and CEO, Regenstrief Foundation
Rachel Patzer
President and CEO, Regenstrief Institute
Sector focus
Frequently asked questions
How does the Regenstrief Institute fund its research operations?
The institute is primarily funded through an endowment established by the late Sam Regenstrief, a manufacturing and retail entrepreneur. Additional research funding comes from federal grants, including those from the National Institutes of Health and the Agency for Healthcare Research and Quality. The institute does not raise external capital or charge licensing fees for LOINC, its most widely adopted tool.
What is LOINC and why is it significant to the institute?
LOINC (Logical Observation Identifiers Names and Codes) is a universal standard for identifying medical laboratory tests, clinical observations, and documents. Developed at Regenstrief starting in 1994, it is now used in more than 175 countries by hospital systems, reference laboratories, and government health agencies to exchange clinical data interoperably. The institute maintains LOINC as an open-access resource, governed through a volunteer committee structure.
What is Regenstrief's relationship to Indiana University?
The Regenstrief Institute is a supporting organization and a component unit of the Indiana University School of Medicine. Many institute investigators hold faculty appointments at IU. The institute's president reports to the dean of the medical school, and the partnership provides Regenstrief with access to clinical environments at IU Health and Eskenazi Health hospitals for research.
Does the Regenstrief Institute make venture capital or private equity investments?
No. The institute operates as a research organization rather than an investment firm. It does not take equity positions in portfolio companies or commit to third-party funds. Its capital base supports internal research programs and technology development, though it contributes to open-source and non-profit data infrastructure.
Who leads investment and operational decisions at Regenstrief?
Operational leadership falls to Rachel Patzer, who became president and CEO in 2023. D. Craig Brater chairs the board and serves as CEO of the separate Regenstrief Foundation. Endowment oversight is governed by the foundation board, but the institute does not publicly disclose its investment committee composition or asset allocation strategy.
Does Regenstrief partner with pharmaceutical companies, and if so, how?
Yes, the institute has maintained research collaborations with major pharmaceutical firms. Merck has partnered on validation studies for digital health technologies, and Eli Lilly has collaborated on real-world data initiatives using Indiana-based clinical datasets. These partnerships are research-oriented rather than commercial — designed to test interventions or generate clinical evidence.
What distinguishes Regenstrief from a typical medical research charity?
Most medical charities fund investigator-initiated research through grants. Regenstrief is a research operating institution: it directly employs investigators, builds and maintains data infrastructure like LOINC and the Indiana Network for Patient Care, and embeds researchers within clinical delivery teams. Its proximity to IU Health's hospitals creates a closed-loop system for studying and improving care delivery.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: